) The Transgenic/Knockout Shared Core Resource is an expansion from the existing transgenic mouse core laboratory to include targeted gene disruption using homologous recombination in embryonic stem (ES) cells and the generation of """"""""knockout"""""""" mice. The facility will also support the in vitro differentiation of ES cells. This core, which began operation in 1990, now consists of has an ES cell/targeted gene disruption facility and a microinjection laboratory. The core provides all the necessary services to support the generation, maintenance, breeding and preservation of transgenic and germ line positive knockout mice. Over the past four and one-half years, the transgenic component of this resource has served 25 different Cancer Center Investigators and generated 241 transgenic founders representing 44 constructs. The new ES cell/gene disruption facility has recently generated four germ line positive knockout mouse lines. In addition, the ES cell laboratory provides technical expertise in growth of ES cells and targeted gene disruption using homologous recombination and instruction of investigators in methods of in vitro ES cell differentiation. The core also provides embryo cryopreservation, strain rederivation, training of Cancer Center investigators, their graduate and postdoctoral students in transgenic technology, models and genetics. This component also provides colony management and maintenance, automated pedigree management, and breeding of all transgenic founders, knockout and experimental breeding colonies. The Transgenic/Knockout core presents a comprehensive service available to Cancer Center investigators for manipulation of the mouse genome. The primary goal is to maintain a state-of-the-art Transgenic/Knockout facility in the Cancer Center that is affordable and accessible to investigators for their studies in cancer biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-15S1
Application #
6664445
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
Guarnieri, A L; Towers, C G; Drasin, D J et al. (2018) The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene 37:3879-3893
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Lyu, Hui; Wang, Shuiliang; Huang, Jingcao et al. (2018) Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 420:97-108
Lee-Sherick, Alisa B; Jacobsen, Kristen M; Henry, Curtis J et al. (2018) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight 3:
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1634 publications